| Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

Non-profit organisations provide an alternative to rescue stalled orphan drugs for biotechs struggling against a lethargic investment climate.

The first is the current packaging, which consists of a box with a big open window that lets customers see what's inside. The ...

Cellares' forward momentum continues, as the company announced April 1, 2025, a notable milestone for its Cell Shuttle.

The added longevity resulting from the medication scheme and its improved level of treatment adherence, amounts to 5.25 years per patient, claims the Bulgarian health insurance agency, NHIF.

Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical ...

ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company”), a development-stage biotechnology company developing new medicines to treat pain and ...

Though Isomorphic is burning through millions in R&D costs now, investors have high hopes for the potential of AI drug ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...